Stellar Biotechnologies, Inc. shares had a trading volume of 16K in the last trading session. Volume was down 83.33% under the stocks average daily volume.
Traders are feeling more bullish on Stellar Biotechnologies, Inc. of late if you consider the downtick in short interest. The company had a fall in short interest between September 29, 2017 and October 13, 2017 of -0.32%. Short shares fell 96 over that period. The days to cover decreased to 0.0 and the short interest percentage is 0.00% as of October 13.
The following firms have recently changed their position in SBOT. As of quarter end Kcg Holdings, Inc. had bought a total of 12,563 shares growing its position 73.4%. The value in dollars went from $65,000 to $49,000 decreasing 24.6% since the last quarter. Creative Planning reduced its stake by shedding 1,400 shares a decrease of 69.3% as of 06/30/2017. Creative Planning now holds 620 shares valued at $1,000. The value of the position overall is down by 66.7%.
The company is now up since yesterday’s close of $1.16. Shares are trading at $1.16 just above the 50 day moving average which is $1.16 and a bit lower than the 200 day moving average of $1.24. The 50 day moving average went up by -0.19% and the 200 day average went down by -6.12%.
As of the last earnings report the EPS was $-0.51 and is projected to be $-0.47 for the current year with 10,520,000 shares outstanding. Next quarter’s EPS is forecasted at $-0.09 with next year’s EPS projected to be $-0.38.
Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. KLH is an immune-stimulating molecule used as an active pharmaceutical ingredient in various new immunotherapies; and as an injectable product to assess immune response. The company manufactures and supplies KLH protein under the Stellar KLH brand. Its products include Stellar KLH protein in various grades, formulations, and configurations for preclinical and clinical applications, as well as certain KLH-based in vitro diagnostic kits for preclinical use. The company’s customers and partners include multinational biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California..